Therapeutic potential of the new quinolones in the treatment of lower respiratory tract infections

Bibliography

• MITSUYAMA J: Structures of existing and new quinolones and relationship to bactericidal activity against Streptococcus pneumoniae. Antimicrob. Chemother. (1999) 44:201–207.
   Web of Science ®Google Scholar
• •An interesting analysis of the relationship between structure and microbiological activity of fluoroquinolones.
   Google Scholar
• ALOVERO F, PAN X-S, MORRIS JE, MANZO RH, FISHER LM: Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisometase IV to gyrase. Antimicrob. Agents Chemother. (2000) 44:320–325.
   PubMed Web of Science ®Google Scholar
• SCHMITZ FJ, HOFMANN B, HANSEN B et al.: Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and mwdfloxacin (BAY 12-8039) MICs and mutations in grIA, grIB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus. Antimicrob. Chemother. (1998) 41:481–484.
   Web of Science ®Google Scholar
• CHANT SK, SINGH M, CHATTERJEE NR: The chemical and biological aspects of fluoroquinolones: reality and dreams. Carr. Pharm. Design (2001) 7:313–337.
   Web of Science ®Google Scholar
• SCHENTAG JJ: Pharmacokynetic and pharmacodynamic predictors of antimicrobial efficacy: Mwdfloxacin and Streptococcus pneumoniae. Chemother. (2002) 14(52):13–21.
   Google Scholar
• ZELENITSKY SA, ARIANO RE, IACOVIDES H, SUN S, HARDING GKM: AUC04/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model. J. Antimicrob. Chemother. (2003) 51:905–911.
   PubMed Web of Science ®Google Scholar
• CROISIER D, CHAVANET P, LEQUEU C et al.: Efficacy and pharmacodynamic of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones. Antimicrob. Chemother. (2002) 50:349–360.
   Web of Science ®Google Scholar
• BLONDEAU JM: Expanded activity and utility of the new fluorquinolones: a review. Clin. Then (1991) 21:3–40.
   Google Scholar
• LACRETA FP, KOLLIA GD, DUNCAN G et al.: Age and Gender effects on the pharmacokinetics of gatifloxacin. Pharmacotherapy (2000) 20:67S–75S.
   Google Scholar
• CHIEN SC, CHOW AT, NATARAJAN J et al: Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral does of levofloxacin in healthy subjects. Antimicrob. Agents Chemother. (1997) 41:1562–1565.
   PubMed Web of Science ®Google Scholar
• NIGHTINGALE CH: Mwdfloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics. Pharmacotherapy (2000) 20:245–256.
   PubMed Web of Science ®Google Scholar
• FORREST A, NIX DE, BALLOW CH, GOSS TF, BIRMINGHAM MC, SCHENTAG JJ: Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. (1993) 37:1073–1081.
   PubMed Web of Science ®Google Scholar
• DALHOFF A: Pharmacodynamics of fluoroquinolones." Antimicrob. Chemother: (1999) 43(Suppl. B):51–59.
   Google Scholar
• DONG Y, ZHAO X, KREISWIRTH B et al: Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. (2000) 44:1756–1758.
   Web of Science ®Google Scholar
• BLONDEAU J, ZHAO X, HANSEN G et al: Mutant prevention concentrations (MPC) for fluoroquinolones with clinical isolates of Streptococcus pneumoniae Antimicrob. Agents Chemother. (2001) 45:433–438.
   PubMed Web of Science ®Google Scholar
• ZHAO X, EISNER W, PERL-ROSENTHAL N, KREISWIRTH B, DRLICA K: Mutant prevention concentration of garenoxacin for ciprofloxacin-susceptible or -resistant Staphylococcus aureus. Antimicrob. Agents Chemother. (2003) 47:1023–1027.
   PubMed Web of Science ®Google Scholar
• JONES RN, MUTNICK A, BIEDENBACH D: Garenoxacin (BM5284756) activity against 8,686 S. pneumoniae including tentative susceptibility testing criteria. 42nd ICAAC, San Diego, CA, USA (2002):151 (Abstract E58).
   Google Scholar
• HOBAN DJ, PALATNICK L, SMITH H, NICHOL K, HOBAN C, ZHANEL GG: Activity of BM5284756 and marketed fluoroquinolones against lower respiratory tract pathogens: results of a 3 year Canadian Surveillance study. 42nd ICAAC, San Diego, CA, USA (2002):153 (Abstract E64).
   Google Scholar
• BOZDOGAN B, KELLY L, JACOBS MR, APPELBAUM PC: Activity of DK507k, a new fluoroquinolone, against quinolone non-susceptible Streptococcus pneumoniae compared to ciprofloxacin, levofloxacin, moxifloxacin, gatifloxacin and sitafloxacin. 42nd ICAAC, San Diego, CA, USA (2002):189 (Abstract F571).
   Google Scholar
• CLARK CL, JACOBS MR, APPELBAUM PC: Time-kill study of antipneumococcal activity of DK507k, a new fluoroquinolone, compared to 5 other agents. 42nd ICAAC, San Diego CA, USA (2002):190 (Abstract F574).
   Google Scholar
• LIN G, PATEL M, GUPTE S et al: Time-kill analysis of the antipneumococcal activity of two new quinolones, WCK771A and WCK919, compared to five other quinolones. 42nd ICAAC, San Diego CA, USA (2002):186 (Abstract F559).
   Google Scholar
• DALHOFF A, SCHMITZ FJ: ha vitro antibacterial activity and pharmacodynamics of new quinolones. Eur. Clin. Microbiol. Infect. Dis. (2003) 22:203–221.
   PubMed Web of Science ®Google Scholar
• ••A critical review of problems encounteredin interpreting and validating microbiological susceptibility data. The most recent complete review of fluoroquinolone in vitro microbiological activity.
   Google Scholar
• HOBAN DJ, BOUCHILLON SK, JOHNSON JL et al: Comparative in vitro potency of gemifloxacin and fluoroquinolones against recent european clinical isolates from a global surveillance study. all j Clin. Microbiol. bfect. Dis. (2001) 20:814–819.
   PubMed Web of Science ®Google Scholar
• DUBOIS J, ST-PIERRE C: ki vitro activity of ABT 492 versus quinolones and macrolides against Legionella spp. 42nd ICAAC, San Diego, CA, USA (2002):185 (Abstract F553).
   Google Scholar
• MILATOVICH D, SCHMITZ FJ, BRISSE S, VERHOEF J, FLUIT AC: In vitro activities of sitafloxacin and six other quinolones against 8.796 clinical bacterial isolates. Antimicrob. Agents Chemother: (2000) 44:1102–1107.
   Google Scholar
• ALDRIDGE KE: Increased activity of a new chlorofluoroquinolone, BAY y3118, compared with activities of ciprofloxacin, sparfloxacin, and other antimicrobial agents against anaerobic bacteria. Antimicrob. Agents Chemother: (1994) 38:1671–1674.
   Google Scholar
• APPELBAUM PC, PATEL M, GUPTE S et al: Anti-anaerobic activity of two new quinolones, WCK771A and WCK919, compared to nine other agents. 42nd ICAAC, San Diego, CA, USA (2002):187 (Abstract F561).
   Google Scholar
• DAVIES BI, MAESEN FP: Clinical effectiveness of levofloxacin in patients with acute purulent exacerbations of chronic bronchitis: the relationship with in-vitro activity. J. Antimicrob. Chemother: (1999) 43 (Suppl. C):83–90.
   Google Scholar
• DE ABATE CA, RUSSEL M, MCELVAINE P et al.: Safety and efficacy of oral levofloxacin versus cefuroxime axetil in acute bacterial exacerbations of chronic bronchitis. Respir. Care (1997) 42:206–213.
   Google Scholar
• HABIB MP, RUSSELL M, DE ABATE CA et al: Multicenter, randomized study comparing efficacy and safety of oral levofloxacin and cefaclor in the treatment of acute exacerbations of chronic bronchitis. Infect. Dis. Clin. Practice (1998) 7:1–9.
   Web of Science ®Google Scholar
• SHAH PM, MAESEN FP, DOLMANN A et al: Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbations of chronic bronchitis: results of a randomized, double-blind study. J. Antimicrob. Chemother: (1999) 43:529–539.
   PubMed Web of Science ®Google Scholar
• WEISS LR: Open-label, randomized comparison of the efficacy and tolerability of clarithromycin, levofloxacin, and cefuroxime axetil in the treatment of adults with acute bacterial exacerbations of chronic bronchitis. Clin. Then (2002) 24:1414–1425.
   PubMed Web of Science ®Google Scholar
• MASTERTON RG, BURLEY CJ: Randomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbations of chronic bronchitis. Int. Antimicrob. Agents (2001) 18:503–512.
   PubMed Web of Science ®Google Scholar
• RAMIREZ A, MOLINA J, HOFMANN Aet al: Gatifloxacin treatment in patients with acute exacerbations of chronic bronchitis: clinical trial results.' Respir: Dis. (1999) 20(11):30s-39s.
   Google Scholar
• DE ABATE CA, MCIVOR RA, MCELVAINE P et al.: Gatifloxacin versus cefuroxime axetil in patients with acute exacerbations of chronic bronchitis. .1. Respir: Dis. (1999) 20(11):23s-29s.
   Google Scholar
• WILSON R, KUBIN R, BALLIN I et al.:Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J. Antimicrob. Chemother: (1999) 44:501–513.
   Google Scholar
• CHODOSH S, DEABATE CA, HAVERSTOCK D et al.: Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Respir: Med. (2000) 94:18–27.
   PubMed Web of Science ®Google Scholar
• KREIS S, HERRERA N, GOLZAR N et al.: A comparison of moxifloxacin and azithromycin in the treatment of acute exacerbations of chronic bronchitis. I Clin. Outcomes Manage. (2000) 7:3337.
   Google Scholar
• DEABATE CA, MATTHEW CP, WARNER JH et al: The safety and efficacy of short course (5-day) moxifloxacin versus azithromycin in the treatment of patients with acute exacerbations of chronic bronchitis. Respic Med. (2000) 94:1029–1037.
   PubMed Web of Science ®Google Scholar
• SCHABERG T, BALLIN I, HUCHON G et al.: A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbations of chronic bronchitis. I Int. Med. Res. (2001) 29:314–328.
   PubMed Web of Science ®Google Scholar
• LORENZ J, THATE-WASCHKE IM, MAST 0 et al.: Treatment outcomes in acute exacerbations of chronic bronchitis: comparison of macrolides and moxifloxacin from the patient perspective. I Int. Med. Res. (2001) 29:74–86.
   Google Scholar
• FILE TM, SEGRETI J, DUBAR L et al.:A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in the treatment of adults with community-acquired pneumonia. Antimicrob. Agents Chemother: (1997) 41:1965–1972.
   Google Scholar
• GEDDES AM, THALER M, SCHONWALD S et al.: Levofloxacin in the empirical treatment of patients with suspected bacteraemia/sepsis: comparison with imipenem/cilastatin in an open, randomised trial. I. Antimicrob. Chemother. (1999) 44:799–810.
   PubMed Web of Science ®Google Scholar
• SULLIVAN J, MCELROY AD, HONSINGER RW et al.: Treating community-acquired pneumonia with once daily gatifloxacin versus once daily levofloxacin. Respic Dis. (1999) 20(S1 1):49s–59s.
   Google Scholar
• RAMIREZ JA, NGUYEN TH, TELLIER G et al.: Treating community-acquired pneumonia with once daily gatifloxacin versus twice daily clarithromycin. Respic Dis. (1999) 20(S11):40s–48s.
   Google Scholar
• FOGARTY C, DOWELL ME, ELLISON WT et al.: Treating community-acquired pneumonia in hospitalised patients: gatifloxacin versus ceftriaxone/ clarithromycin. Respic Dis. (1999) 20(S11):S60–S69.
   Google Scholar
• DRESSER LD, NIEDERMAN MS, PALADINO JA: Cost-effectiveness of gatifloxacin versus ceftriaxone with a macrolide for the treatment of community-acquired pneumonia. Chest (2001) 119:1439–1448.
   PubMed Web of Science ®Google Scholar
• FOGARTY C, GROSSMAN C, WILLIAMS J et al.: Efficacy and safety of moxifloxacin versus clarithromycin for community-acquired pneumonia. Infect. Med. (1999) 16:748–763.
   Web of Science ®Google Scholar
• HOEFFKEN G, MEYER HP, WINTER J et al.: The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia. Respic Med. (2001) 95:553–564.
   PubMed Web of Science ®Google Scholar
• PETITPRETZ P, ARVIS P, MARCEL M et al.: Oral moxifloxacin versus high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. Chest (2001) 119:185–195.
   PubMed Web of Science ®Google Scholar
• FINCH R, SCHURMANN D, COLLINS 0 et al: Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared to sequential i.v and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Drugs (2002) 62:13–59.
   Google Scholar
• ANDREWS JM, HONEYBOURNE D, JEVONS G, BRENWALD NP, CUNNINGHAM B, WISE R: Concentration of levofloxacin in the respiratory tract following a single oral doses in patients undergoing fibre-optic bronchoscopy. Antimicrob. Chemother. (1997) 40:573–577.
   Web of Science ®Google Scholar
• BALL P, FERNALD A, TILL OTSON G: Therapeutical advances of new fluoroquinolones. Expert Opin. Invert. Drugs (1998) 7:761–783.
   PubMedGoogle Scholar
• LEGG JM, BINT AJ: Will pneumococci put quinolones in their place. I Antimicrob. Chemother: (1999) 44:425–427.
   PubMed Web of Science ®Google Scholar
• CHEN DK, MCGEER A, DE AZAVEDO JC, LOW DE: Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl. J. Med. (1999) 341:233–239.
   PubMed Web of Science ®Google Scholar
• ZHANEL GG, EMIS K, VERCAINGE L et al: A critical review of the fluoroquinolones: focus on respiratory tract infections. Drugs (2002) 62:13–59.
   PubMed Web of Science ®Google Scholar
• ••An exhaustive, updated review on the roleof fluoroquinolones in respiratory infection. The review ranges from chemistry to pharmacoeconomical considerations.
   Google Scholar
• SCHELD WM: Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg. Infect. Dis. (2003) 9:1–9.
   PubMed Web of Science ®Google Scholar
• HO PL, YUNG RW, TSANG DN et al.: Increasing resistance of S. pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000.1 Antimicrob. Chemother: (2001) 48:659–665.
   Google Scholar
• DOERN GV, HEILMANN KP, HUYNH HK, RHOMBERG PL, COFFMAN SL, BRUEGGEMANN AB: Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance since 1994-1995. Antimicrob. Agents Chemother. (2001) 45:1721–1729.
   PubMed Web of Science ®Google Scholar
• NIEDERMAN MS: Guidelines for the management of community-acquired pneumonia. Med. Clin. North Am. (2001) 85:1493–1509.
   PubMed Web of Science ®Google Scholar
• ••An excellent overview of current leadingguidelines for the treatment of CAP. This review approaches issues of interest in the choice of antimicrobial agents and specifically addresses the role and choice of fluoroquinolones in pneumonia.
   Google Scholar
• FUKUDA H, HIRAMATSU K: Primary targets of fluoroquinolones in Streptococcus pneumoniae. Antimicrob. Agents Chemother. (1999) 43:410–412.
   PubMed Web of Science ®Google Scholar
• PIDDOCK LJ: Mechanisms of resistance to fluoroquinolones: state of the art 1992-1994. Drugs (1995) 49(2):29–35.
   PubMedGoogle Scholar
• HOOPER DC: Emerging mechanisms of fluoroquinolone resistance. Emerg. Infect. Dis. (2001) 7:337–341.
   PubMed Web of Science ®Google Scholar
• HOOPER DC: Mechanism of quinolone resistance. Drug Resistance Updates (1999) 2:38–55.
   PubMed Web of Science ®Google Scholar
• KOHLER T, PECHERE JC: Bacterial resistance to quinolones. In: The Quinolones (2nd Ed.). VT Andriole (Ed.), Academic Press, San Diego, CA, USA (1998):117–142.
   Google Scholar
• BOS WELL FJ, ANDREWS JM, JEVONS G, WISE R: Comparison of in vitro activities of several new quinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance. Antimicrob. Chemother. (2002) 50:495–502.
   Web of Science ®Google Scholar
• BOLHUIS H, VAV VEEN HW, POOLMAN B, DRIESSEN AJ et al.: Mechanisms of multidrug transporters. FEMS Microbiol Rev (1997) 21:55–84.
   PubMed Web of Science ®Google Scholar
• MARTINEZ-MARTINEZ L, PASCUAL A, JACOBY GA: Quinolone resistance from a transferable plasmid. Lancet (1998) 351:797–799.
   PubMed Web of Science ®Google Scholar
• DRILICA K: A strategy for fighting antibiotic resistance. ASM News (2001) 67:27–33.
   Google Scholar
• BRENWALD NP, GILL MJ, WISE R: Prevalence of a putative efflux mechanism among fluoroquinolone-clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. (1998) 42:2032–2035.
   PubMed Web of Science ®Google Scholar
• Resistance of Streptococcus pneumoniae to fluoroquinolones - United States, 1995-1999. MMWR (2001) 50(37):800–804.
   PubMedGoogle Scholar
• •Centers for Disease Control report on fluoroquinolones resistance rates in US during 1995-1999.
   Google Scholar
• DAVIDSON R, CAVALCANTI R, BRUNTON JL et al.: Brief report: resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl. Med. (2002) 346:747–750.
   PubMed Web of Science ®Google Scholar
• WEISS K, RESTIERI C, GAUTHIER R et al.: A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae. Clin. Infect. Dis. (2001) 33:517–522.
   PubMed Web of Science ®Google Scholar
• HO PL, ISE WS, TSANG KWT et al: Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumonia a a case control study. Clin. Infect. Dis. (2001) 33:701–707.
   Web of Science ®Google Scholar
• URBAN C, RAHMAN N, ZHAO X, MARIANO S et al.: Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy. Infect. Dis. (2001) 184:794–798.
   Web of Science ®Google Scholar
• HOOPER DC: New uses for new and old quinolones and the challenge of resistance. Clin. Infect. Dis. (2000) 30:243–254.
   PubMed Web of Science ®Google Scholar
• MENZIES DJ, DORSAINVIL PA, CUNHA BA et al.: Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents. Am. J. Med. (2002) 113:232–234.
   PubMed Web of Science ®Google Scholar
• STHALMANN R, LODE H: Toxicity of quinolones. Drugs (1999) 58\(Suppl. 2):37–42.
   Google Scholar
• LEWIS JR, GUMS JG, DICKENSHEETS DL: Levofloxacin-induced bilateral Achilles tendinitis. Ann. Pharmacother. (1999) 33:792-795. ao.BLONDEAU JM: Clinical utility of the new fluoroquinolones for treating respiratory and urinary tract infections. Expert Opin. Investig. Drugs (2001) 10:213–237.
   Google Scholar
• BALL P, MANDELL L, NIKI Y, TILLOTSON G: Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Safety (1999) 21:407–421.
   PubMed Web of Science ®Google Scholar
• WILSON R, LANGAN C, BALL P, BATEMAN K, PYPSTRA R: Oral gemifloxacin once daily for five days compared with sequential therapy with IV ceftriaxone/oral cefuroxime (max of 10 days) in the treatment of hospitalised patients with acute exacerbations of chronic bronchitis. Respir. Med. (2003) 97:242–249.
   PubMed Web of Science ®Google Scholar
• LODE H, FILE TM, MANDELL LA, BALL P, PYPSTRA R, THOMAS M: Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalised with community-acquired pneumonia: randomized, open label, multicenter study of clinical efficacy and tolerability. Clin. The]: (2002) 24:1915–1936.
   Google Scholar